Article Text

Download PDFPDF
CASE REPORT
Thoracic involvement of diffuse lymphangiomatosis successfully treated with sildenafil
  1. Arnaud Maurac1,
  2. Marie-Pierre Debray2,
  3. Bruno Crestani3,4 and
  4. Camille Taillé3,4
  1. 1 Centre Hospitalier Universitaire de Nancy, Département de pneumologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France
  2. 2 Service de Radiologie, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France
  3. 3 Service de Pneumologie et Centre de Référence Constitutif des Maladies Pulmonaires Rares, Hôpital Bichat, Assistance Publique - Hôpitaux de Paris, Paris, France
  4. 4 Département Hospitalo-Universitaire FIRE; INSERM UMR 1152; LabEx Inflamex, Université Paris Diderot, UFR de Médecine Site Xavier-Bichat, Paris, France
  1. Correspondence to Professor Camille Taillé, camille.taille{at}aphp.fr

Abstract

General lymphatic anomaly (GLA) is a very rare disorder, characterised by multifocal lymphatic malformations into various tissues that is due to congenital abnormalities of lymphatic development. No treatment has ever proved its efficiency.

We report a 22-year-old man with recurrent bronchial casts due to thoracic involvement of GLA. After a 6-month treatment with sildenafil (20 mg three times a day), a phosphodiesterase 5 inhibitor, chest CT scan showed a complete regression of ground-glass opacities and lung function test results improved substantially and remained stable for 1 year. The treatment was well tolerated.

This observation suggests that sildenafil may be a therapeutic approach to be tested in thoracic involvement of GLA.

  • interstitial lung disease
  • drugs: respiratory system
View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors AM and CT: concept, design, supervision, processing, writing manuscript and critical analysis. BC: critical analysis. M-PD: CT scan analysis and approved the manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.